Tenax Therapeutics (TENX) Set to Announce Earnings on Wednesday

Tenax Therapeutics (NASDAQ:TENX) is expected to announce its Q3 2026 resultson Wednesday, November 11th. Analysts expect Tenax Therapeutics to announce earnings of ($0.35) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 12:30 PM ET.

Tenax Therapeutics Stock Up 2.2%

Shares of Tenax Therapeutics stock opened at $1.84 on Wednesday. The stock has a market cap of $68.85 million, a P/E ratio of -1.24 and a beta of 0.99. Tenax Therapeutics has a 12-month low of $1.31 and a 12-month high of $19.40. The business’s 50 day moving average is $1.84 and its 200-day moving average is $9.96.

Insider Buying and Selling

In other Tenax Therapeutics news, Director Declan Doogan bought 53,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were acquired at an average cost of $1.92 per share, with a total value of $101,760.00. Following the acquisition, the director owned 55,274 shares of the company’s stock, valued at $106,126.08. The trade was a 2,330.69% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Adar1 Capital Management, Llc purchased 331,979 shares of the company’s stock in a transaction that occurred on Wednesday, October 21st. The stock was acquired at an average price of $1.66 per share, for a total transaction of $551,085.14. Following the purchase, the insider owned 7,447,000 shares in the company, valued at $12,362,020. This trade represents a 4.67% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 3,682,899 shares of company stock valued at $6,388,279. Insiders own 10.81% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on TENX. Canaccord Genuity Group set a $4.00 target price on shares of Tenax Therapeutics and gave the stock a “buy” rating in a report on Tuesday, August 11th. William Blair cut shares of Tenax Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, August 10th. UBS Group downgraded shares of Tenax Therapeutics to a “neutral” rating in a research report on Monday, August 31st. Leerink Partners set a $4.00 price objective on shares of Tenax Therapeutics in a research note on Tuesday, August 11th. Finally, Chardan Capital lowered shares of Tenax Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 price objective on the stock. in a research note on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $14.00.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.